Biointerventional solutions for heart failure, chronic myocardial ischemia, and acute myocardial infarction


October 4, 2017
Biocardia Receives U.S. Patent Covering Morph Product Family Design

September 27, 2017
Biocardia Announces Successful Interim Safety Analysis in its Phase 3 Clinical Trial of Cardiamp Stem Cell Therapy for Heart Failure

September 19, 2017
BioCardia Announces Publication of 12-Month Results from Phase II TRIDENT Clinical Trial That Shows Positive Safety Profile for Allogeneic Bone Marrow Stem Cells Delivered with Helix Transendocardial Delivery System

September 15, 2017
BioCardia’s CardiAMP Heart Failure Trial Design to be Presented at Texas Heart Institute International Symposium on Cardiovascular Regenerative Medicine

September 7, 2017
BioCardia receives US Patent covering a method of preparing and characterizing mesenchymal cells, providing further protection to CardiALLO cell therapy program

July 26, 2017
BioCardia Completes Roll-in Cohort in Pivotal Phase III CardiAMP Heart Failure Trial

May 24, 2017
Study Shows Helix Transendocardial Delivery System Enables Greater Myocardial Retention of Stem Cell Therapy

April 26, 2017
BioCardia to Present at the 5th Annual Cell & Gene Investor Day

February 28, 2017
Johns Hopkins Medicine, Maryland Stem Cell Research Fund and BioCardia Announce First Patient Treated with CardiAMP Cell Therapy for Ischemic Heart Failure in Phase III Clinical Trial

more news



We are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. BioCardia is developing proprietary comprehensive  biotherapeutic solutions for cardiovascular disease in its CardiAMP™ and CardiALLO™ therapies. Clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. 

These programs are enabled by the Company's Helix transendocardial delivery systems and Morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.